Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 18221-18230 Newer>

The Motley Fool November 9, 2006 Shannon Zimmerman	The Best Blue Chip for 2007: FedEx You get the best of both worlds with FedEx: a greater rate of anticipated earnings growth without a valuation premium. Investors, can you say "margin of safety?"
The Motley Fool November 9, 2006 Joseph Khattab	The Best Blue Chip for 2007: Bank of America Bank of America pays out a saucy 4.1% dividend, and it trades at lower earnings multiples than most of its peer group. It also looks reasonably valued compared to its historical multiples.
The Motley Fool November 9, 2006 Jim Fink	The Best Blue Chip for 2007: Costco Efficiency and growth make Costco a retailing blue chip.
The Motley Fool November 8, 2006 Tim Beyers	Who's Buying Now? Sometimes insiders are buying for all the right reasons. Who's at it this week? CBIZ... Intervoice... Jefferies Group... Orthofix... etc.
The Motley Fool November 8, 2006 Brian Lawler	Barr's Wounded Quarter If your revenues live by the generic sword, they can die by it, too. That seems to be the case today for Barr Pharmaceuticals. Investors, take note.
The Motley Fool November 8, 2006 Matthew Crews	Peet's Keeps Percolating If you like to invest in growth stories, then Peet's Coffee & Tea should be on your research list.
The Motley Fool November 8, 2006 Anders Bylund	Foolish Forecast: Challenges for Cisco The networking infrastructure powerhouse gets ready to report earnings for first-quarter 2007. Investors, do you want to know what Wall Street expects to see? Do you want to know what really matters?
The Motley Fool November 8, 2006 Nathan Parmelee	Boston Beer's Becoming More Potent It's tough to argue with the third-quarter results released by Boston Beer. As the largest brewer of craft beers, its growth is impressive -- and a bit surprising.
The Motley Fool November 8, 2006 Alyce Lomax	Entercom Dials It Down The radio station owner's third quarter wasn't music to investors' ears.
The Motley Fool November 8, 2006 Brian Lawler	Will Santarus Heal Investors' Heartburn? This pharma's fortunes will rise or fall on its single drug. In a few quarters, investors should be able see if this is worth their consideration.
<Older 18221-18230 Newer> Return to current articles.